FI113621B - Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi - Google Patents

Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi

Info

Publication number
FI113621B
FI113621B FI943626A FI943626A FI113621B FI 113621 B FI113621 B FI 113621B FI 943626 A FI943626 A FI 943626A FI 943626 A FI943626 A FI 943626A FI 113621 B FI113621 B FI 113621B
Authority
FI
Finland
Prior art keywords
recombinant adenovirus
preparation
cell mediated
mediated immunity
warm blooded
Prior art date
Application number
FI943626A
Other languages
English (en)
Swedish (sv)
Other versions
FI943626A0 (fi
FI943626A (fi
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur Sha Murthy
Shaw-Guang Lin Lee
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of FI943626A0 publication Critical patent/FI943626A0/fi
Publication of FI943626A publication Critical patent/FI943626A/fi
Application granted granted Critical
Publication of FI113621B publication Critical patent/FI113621B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
FI943626A 1993-08-11 1994-08-04 Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi FI113621B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10523293A 1993-08-11 1993-08-11
US27628994A 1994-07-20 1994-07-20

Publications (3)

Publication Number Publication Date
FI943626A0 FI943626A0 (fi) 1994-08-04
FI943626A FI943626A (fi) 1995-02-12
FI113621B true FI113621B (fi) 2004-05-31

Family

ID=26802374

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943626A FI113621B (fi) 1993-08-11 1994-08-04 Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi

Country Status (17)

Country Link
EP (1) EP0638316B1 (fi)
JP (1) JPH07145079A (fi)
KR (1) KR100347220B1 (fi)
AT (1) ATE241385T1 (fi)
AU (2) AU6889194A (fi)
BR (1) BR9403202A (fi)
CA (1) CA2130202A1 (fi)
DE (1) DE69432730T2 (fi)
DK (1) DK0638316T3 (fi)
ES (1) ES2196018T3 (fi)
FI (1) FI113621B (fi)
HK (1) HK1009934A1 (fi)
HU (1) HUT69793A (fi)
IL (1) IL110560A (fi)
NZ (1) NZ264190A (fi)
PT (1) PT638316E (fi)
SG (1) SG43029A1 (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
EP0935659A1 (en) * 1996-09-17 1999-08-18 Chiron Corporation Compositions and methods for treating intracellular diseases
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
JP2005517639A (ja) 2001-11-30 2005-06-16 イシス イノベーション リミテッド ワクチン
BRPI0504782A (pt) 2005-11-01 2007-09-18 Fundacao Oswaldo Cruz adenovìrus recombinantes, processo de construção de adenovìrus recombinantes, composição de vacina contra toxoplasmose, e método de imunização contra infecções causadas pelo parasita t. gondii

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU576907B2 (en) * 1984-11-01 1988-09-08 American Home Products Corporation Oral vaccines comprising live recombinant adenoviruses
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
ATE163676T1 (de) * 1990-10-17 1998-03-15 Us Health Molekulare klone von hiv-1 und deren verwendung
AU9179891A (en) * 1990-12-19 1992-07-22 Epitope, Inc. Hiv reverse transcriptase vaccine
ES2201055T3 (es) * 1992-08-07 2004-03-16 Wyeth Vacunas de adenovirus recombinante.

Also Published As

Publication number Publication date
BR9403202A (pt) 1995-04-11
FI943626A0 (fi) 1994-08-04
DE69432730D1 (de) 2003-07-03
DK0638316T3 (da) 2003-09-22
IL110560A (en) 1998-10-30
DE69432730T2 (de) 2004-03-25
NZ264190A (en) 1997-06-24
KR950005326A (ko) 1995-03-20
AU6889194A (en) 1995-02-23
JPH07145079A (ja) 1995-06-06
HU9402309D0 (en) 1994-10-28
AU4850697A (en) 1998-03-26
KR100347220B1 (ko) 2003-02-26
FI943626A (fi) 1995-02-12
SG43029A1 (en) 1997-10-17
IL110560A0 (en) 1994-11-11
EP0638316A1 (en) 1995-02-15
HUT69793A (en) 1995-09-28
PT638316E (pt) 2003-10-31
ES2196018T3 (es) 2003-12-16
CA2130202A1 (en) 1995-02-12
HK1009934A1 (en) 1999-06-11
ATE241385T1 (de) 2003-06-15
EP0638316B1 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
PT586076E (pt) Vacinas de adenovirus recombinantes
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
EP0759935A4 (en) RECOMBINANT PAPILLOMAVIRUS L1
EP1033995A4 (en) INSECT CELLS OR FRAGMENTS FOR USE AS ANTIGEN ADJUVANTS
FI113621B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
NZ238833A (en) Equine herpesvirus-4 gh or gc polypeptides, nucleic acids encoding them and vaccines therefrom
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
IL91609A0 (en) Allelic variants of plasmodium falciparum merozoite surface antigen
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.